Assessing Ascletis Pharma (SEHK:1672) Valuation After Substantial Share Price Surge

Ascletis Pharma (SEHK:1672) shares have been in focus lately, with investors watching for developments that might affect its outlook. Recent stock movement has prompted curiosity about what could be driving sentiment around this Hong Kong-listed biotech company.

See our latest analysis for Ascletis Pharma.

Ascletis Pharma’s share price has shown strong momentum in 2024, surging 235.8% year-to-date and rebounding 22.4% over the past three months, despite some choppiness in recent weeks. The company’s 1-year total shareholder return of 677.1% easily stands out among its peers, which may reflect investor optimism for both its near-term prospects and longer-term growth story.

If Ascletis’s run has you thinking about the next breakout in healthcare, you’ll want to see the latest movers with our See the full list for free.

But with shares soaring and investors piling in, the central question remains: Is Ascletis Pharma still trading below fair value, or are expectations for future growth already fully reflected in the price?

Ascletis Pharma shares trade at a price-to-book ratio of 5.3x, notably below peer and industry averages, despite the recent surge in price.

The price-to-book ratio compares a company’s market value to its book value. It provides a benchmark for asset-based valuation in asset-heavy sectors such as biotech. A lower ratio can suggest undervaluation if underlying growth prospects remain strong, especially when paired with rapid revenue expansion.

At 5.3x, Ascletis appears attractively valued compared to the Hong Kong Biotechs industry average of 6x and even more so when measured against the peer average of 12x. This significant discount to peers highlights market caution or perhaps skepticism about profitability. It also points to potential for re-rating should growth materialize as forecast.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Book of 5.3x (UNDERVALUED)

However, rapid revenue growth is offset by minimal net income gains. Lingering skepticism about sustained profitability could still weigh on investor confidence.

Find out about the key risks to this Ascletis Pharma narrative.

If you have a different perspective or want to delve deeper into Ascletis Pharma’s numbers, it only takes a few minutes to build your own view. Do it your way

A great starting point for your Ascletis Pharma research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

Don’t wait for the next big move to pass you by. Simply Wall Street’s screeners are your shortcut to tomorrow’s standout opportunities and untapped winners.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include 1672.HK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com